Latest Ratios: P/E Ratio -12.4x · EV/EBITDA N/A · ROE -35.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $2.8B | $1.8B | $1.3B | $21M | $23M | $166M |
| Enterprise Value | $2.8B | $2.7B | $1.6B | $931M | $-172601544 | $-57656310 | $183M |
| P/E Ratio → | -12.44 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 3.57 | 3.79 | 3.95 | 3.73 | 0.12 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -35.9% | -35.9% | -27.7% | -29.3% | -83.3% | — | — |
| ROA | -32.6% | -32.6% | -25.3% | -26.9% | -32.0% | -71.4% | -490.9% |
| ROIC | -38.0% | -38.0% | -72.6% | — | — | — | — |
| ROCE | -38.0% | -38.0% | -31.6% | -34.8% | -37.0% | -99.1% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.07 | 0.01 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -0.37 | -1.04 | -1.09 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -57.73 | -57.73 | -189.56 | — | — | -14.33 | -4.98 |
Net cash position: cash ($91M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 21.94 | 21.94 | 21.17 | 17.06 | 8.79 | 6.74 | 0.20 |
| Quick Ratio | 21.94 | 21.94 | 21.17 | 17.06 | 8.79 | 6.74 | 0.20 |
| Cash Ratio | 21.59 | 21.59 | 21.01 | 16.81 | 8.62 | 6.56 | 0.18 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $35M | $28M | $22M | $1M | $801467 | $2M |
Clinical trial endpoint failure
As reported in financial statements, IRON's ROIC has trended downward from -7.1% in 2025Q1 to -8.1% by 2026Q1, reflecting the company's inability to generate positive returns on invested capital while it continues to aggressively fund its clinical-stage hematologic pipeline through significant R&D expenditures.
The persistent negative ROIC suggests that the capital deployed into the business is currently failing to create economic value, which is typical for pre-revenue biotech firms but warrants caution regarding the efficiency of current trial spending. Investors should monitor whether the company can improve these returns as it approaches potential commercialization, or if the cost of capital will continue to outpace the value of its clinical progress.
Based on recent SEC filings, IRON maintains a current ratio of 24.00, yet this figure appears misleading as it reflects a lack of current liabilities rather than a robust liquidity position, given the rapid depletion of cash reserves observed over the last ten quarters.
While the high current ratio might suggest financial strength, it is a structural artifact of the company's clinical-stage status and minimal operational liabilities. The true liquidity risk is better captured by the accelerating cash burn, which necessitates frequent capital market access and creates ongoing dilution risk for shareholders.
According to historical balance sheet data, IRON maintains a low debt-to-equity ratio of 0.05, indicating that the company has avoided traditional debt financing in favor of equity-based capital raises to fund its ongoing research and development activities throughout the current development cycle.
The absence of significant debt service obligations provides some flexibility, but the reliance on equity markets to sustain operations leaves the company highly sensitive to sector-specific sentiment and interest rate environments. This capital structure strategy appears designed to preserve cash for clinical milestones, though it shifts the burden of financing entirely onto existing shareholders.
As noted in industry research, the P/B ratio of 3.57 is frequently misapplied to IRON, as it fails to account for the intangible value of the company's intellectual property and clinical pipeline, which are not adequately captured by traditional book value accounting methods.
Using book value to assess a clinical-stage firm like IRON obscures the potential terminal value of its drug candidates, which are the primary drivers of its market valuation. Analysts should instead focus on probability-adjusted net present value (rNPV) models that incorporate clinical trial success probabilities and potential market penetration for rare disease therapies.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRON stock.
Disc Medicine, Inc.'s current P/E ratio is -12.4x. This places it at the 50th percentile of its historical range.
Disc Medicine, Inc.'s return on equity (ROE) is -35.9%. The historical average is -44.1%.
Based on historical data, Disc Medicine, Inc. is trading at a P/E of -12.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.